Cancer reports (Hoboken, N.J.) · 2026
Survival Outcomes With Cadonilimab Versus PD-(L)1 Therapy in Front-Line Gastric Cancer: A Network Meta-Analysis.
Network Meta-AnalysisСтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Zi-Kun, Yi Jia-Hong, Xue Ju, Huang Yu-Chen, Zhao Yue, Jiang Chang, Yin Chen-Xi, Xia Biao, Zhou Yi-Xin, He Wen-Zhuo, Xia Liang-Ping
Аннотация
BACKGROUND: The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk-benefit profile for patients with low PD-L1 expression remains unclear in front-line treatment of HER2-negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD-(L)1 therapy. The first PD-1/CTLA-4 bispecific antibody (BsAb), cadonilimab, has been approved, but it is unknown if it can extend the PD-(L)1 regimen to lower PD-L1 patients.
AIMS: To indirectly compare the survival outcomes of cadonilimab versus PD-(L)1 therapy in first-line HER2-negative gastric and gastroesophageal junction cancer, with particular focus on patients with low PD-L1 expression, using a network meta-analysis.
METHODS: Randomized controlled trials with ICIs as first-line treatment were searched in public databases and FDA ODAC up to December 31, 2024. A network meta-analysis was conducted to evaluate the efficacy and safety of approved ICI-based treatments to refine the optimal approach for front-line GC/GEJ.
RESULTS: A total of 7127 patients from eight Phase III trials were included. All ICIs-based therapies significantly improved overall survival (OS) compared to chemotherapy. In indirect comparisons, cadonilimab plus XELOX was associated with numerically more favorable OS (HR = 0.78, 95% CI: 0.62-0.98) compared with PD-(L)1 inhibitors. Numerical trends toward longer survival were observed across subgroups, including patients with PD-L1 < 10 (HR = 0.77, 95% CI: 0.58-1.01) and liver metastasis (HR = 0.67, 95% CI: 0.49-0.93), both historically considered immunotherapy-insensitive populations. All ICIs improved PFS compared to chemotherapy. Cadonilimab was associated with numerically better PFS versus PD-(L)1 inhibitors in indirect comparisons (HR = 0.70, 95% CI: 0.57-0.86). The safety analysis showed no significant increase in severe adverse events.
CONCLUSIONS: In this indirect comparison, cadonilimab showed more favorable survival outcomes versus PD-(L)1 inhibitors in first-line GC/GEJ. Subgroup benefits were observed in liver metastasis, while the PD-L1 < 10 subgroup showed numerical trends. These results highlight the importance of selecting appropriate ICIs to optimize outcomes.
AIMS: To indirectly compare the survival outcomes of cadonilimab versus PD-(L)1 therapy in first-line HER2-negative gastric and gastroesophageal junction cancer, with particular focus on patients with low PD-L1 expression, using a network meta-analysis.
METHODS: Randomized controlled trials with ICIs as first-line treatment were searched in public databases and FDA ODAC up to December 31, 2024. A network meta-analysis was conducted to evaluate the efficacy and safety of approved ICI-based treatments to refine the optimal approach for front-line GC/GEJ.
RESULTS: A total of 7127 patients from eight Phase III trials were included. All ICIs-based therapies significantly improved overall survival (OS) compared to chemotherapy. In indirect comparisons, cadonilimab plus XELOX was associated with numerically more favorable OS (HR = 0.78, 95% CI: 0.62-0.98) compared with PD-(L)1 inhibitors. Numerical trends toward longer survival were observed across subgroups, including patients with PD-L1 < 10 (HR = 0.77, 95% CI: 0.58-1.01) and liver metastasis (HR = 0.67, 95% CI: 0.49-0.93), both historically considered immunotherapy-insensitive populations. All ICIs improved PFS compared to chemotherapy. Cadonilimab was associated with numerically better PFS versus PD-(L)1 inhibitors in indirect comparisons (HR = 0.70, 95% CI: 0.57-0.86). The safety analysis showed no significant increase in severe adverse events.
CONCLUSIONS: In this indirect comparison, cadonilimab showed more favorable survival outcomes versus PD-(L)1 inhibitors in first-line GC/GEJ. Subgroup benefits were observed in liver metastasis, while the PD-L1 < 10 subgroup showed numerical trends. These results highlight the importance of selecting appropriate ICIs to optimize outcomes.